TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03437785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg
Description: Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
Study: NCT02716272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab
Description: Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
Study: NCT01285856

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hair and saliva samples
Description: Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. This non-invasive sampling is more informative than blood tests, as it gives a retrospective profile of an individual's consumption over several months.~Saliva sample, a method which gives similar results without the need for venous blood sampling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hair and saliva samples
Description: Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. This non-invasive sampling is more informative than blood tests, as it gives a retrospective profile of an individual's consumption over several months.~Saliva sample, a method which gives similar results without the need for venous blood sampling.
Study: NCT00603278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: GW685698X

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04943614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodex balance system
Description: BIODEX stability system (BIODEX Medical Systems Inc; Shirley, New York) offers a system that can deliver particular hip and ankle postural training strategy with external biofeedback as a monitor to enhance the reduced subclinical limitations of patients with diabetic neuropathy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional exercises
Description: balance board exercises, walking on different surfaces, Wobble board exercise and parallel bars for ambulatory training, range of motion exercises, foot care as a home program. Same duration treatment
Study: NCT02389894

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embol-X Embolic Protection Device
Description: per the manufacturer's instructions for use (IFU).
Study: NCT03437785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebamipide 100mg
Description: Rebamipide 100mg Tab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of the CKD-495 75mg
Description: Placebo of the CKD-495 75mg Tab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of the CKD-495 75mg
Description: Placebo of the CKD-495 75mg Tab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of the CKD-495 75mg
Description: Placebo of the CKD-495 75mg Tab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of the CKD-495 75mg
Description: Placebo of the CKD-495 75mg Tab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of the CKD-495 150mg
Description: Placebo of the CKD-495 150mg Tab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of the CKD-495 150mg
Description: Placebo of the CKD-495 150mg Tab.
Study: NCT00933543

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PDT
Description: Photodynamic Therapy - Light dose 37 J/cm2
Study: NCT03437785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of the CKD-495 150mg
Description: Placebo of the CKD-495 150mg Tab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of the CKD-495 150mg
Description: Placebo of the CKD-495 150mg Tab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Description: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
Study: NCT00933543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDT
Description: Photodynamic Therapy - Light dose 37 J/cm2
Study: NCT03437785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Description: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Description: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Description: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of the Rebamipide 100mg
Description: Placebo of the Rebamipide 100mg Tab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of the Rebamipide 100mg
Description: Placebo of the Rebamipide 100mg Tab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of the Rebamipide 100mg
Description: Placebo of the Rebamipide 100mg Tab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of the Rebamipide 100mg
Description: Placebo of the Rebamipide 100mg Tab
Study: NCT04374890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP308
Description: 3 weeks of baseline followed by 2x3 weeks use of the test device
Study: NCT01044082

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: controlled cord traction
Description: In the intervention group, controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical signs of placental separation
Description: Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
Study: NCT03690388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Tablets containing 60-mg or 20-mg cabozantinib once daily orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.
Study: NCT03984422

Intervention type: OTHER
Intervention: Smartphone application
Description: use of smartphone application during 2 weeks to 3 months to collect frequency and duration of crises, RCS, photography of finger.
Study: NCT02006277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib prototype microsphere 0.529 mg/mg
Description: Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib prototype microsphere 0.470 mg/mg
Description: Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib prototype microsphere 0.420 mg/mg
Description: Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib oral solution
Description: Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib prototype microsphere 0.529 mg/mg
Description: Subjects will receive a single 250-mg oral dose of crizotinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib prototype microsphere 0.470 mg/mg
Description: Subjects will receive a single 250-mg oral dose of crizotinib.
Study: NCT03794310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPF-08 （1-day treatment）
Description: NPF-08 will be administered on the day of colonoscopy.
Study: NCT02006277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib prototype microsphere 0.420 mg/mg
Description: Subjects will receive a single 250-mg oral dose of crizotinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib capsule
Description: Subjects will receive a single 250-mg oral dose of crizotinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib oral solution
Description: Subjects will receive a single 250-mg oral dose of crizotinib.
Study: NCT03794310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPF-08 （2-day split dose）
Description: NPF-08 will be administered at 2 days divided into the day before and on the day of colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moviprep（1-day treatment）
Description: Moviprep will be administered on the day of colonoscopy.
Study: NCT04123405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to acetylcysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to acetylcysteine
Study: NCT04648865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537031
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT01466946

Intervention type: BEHAVIORAL
Intervention: semi-structured interviews
Description: Use semi-structured interview methods to gather narrative data from research participants, as more open-ended interviews allow participants to share information that is most relevant to their own experiences (Patton, 2002; Rubin \& Rubin, 2005; Kvale, 1996). Semi-structured interviewing can generate a rich understanding of a participant's life routines, experiences, and attitudes related to a topic of inquiry, and can yield a nuanced and thorough description of a research participant's life story and belief systems.
Study: NCT01666756

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chinese herbal formulation PHY906
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03482492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol iv

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol iv
Study: NCT01989806

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic-assisted body weight supported treadmill training (Lokomat V6, Hocoma AG, Switzerland)
Study: NCT01666756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02984358

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Animal protein based diet
Study: NCT01989806

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Passive lower limbs mobilization training (Motomed Vivo 2, RECK, Germany)
Study: NCT02984358

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-nucleotide mycoprotein based diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-nucleotide mycoprotein based diet
Study: NCT03715608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological Intervention
Description: The patients in the intervention group received psychological counseling and corresponding medication after the operation. Psychotherapy was based on the clinical expertise of the psychosocial specialist from Peking University Sixth Hospital, who selected the most appropriate plan for each patient.
Study: NCT01110031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Anti-CD20 monoclonal antibody
Study: NCT01294969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-4943A
Description: Once daily topical ocular allergy medication used for 7 days
Study: NCT02888288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health Intervention
Description: Includes a standard format of greetings, review of last session content, homework discussion, new topic, assigning homework and ends with a fun activity, relaxation or game. First session is a joint session with youth and caregivers. Topics include common stresses and worries experienced by HIV+ youth; relaxation and coping techniques; cognitive behavioral triangle; story of finding out HIV status and if willing, to discuss this in an individual session, peer group session, and with caregiver; identify circles of support; discuss stigma and how to disclose HIV status to others; consider values, hopes and dreams for the future, and how to use this information to live positively with HIV. ART adherence is woven into case examples and discussions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care includes enhanced ART adherence based on clinic protocols and monthly HIV teaching sessions prior to adolescent clinic.
Study: NCT01169623

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance
Description: 55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance
Description: 55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
Study: NCT03246685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imprime PGG
Description: Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imprime PGG
Description: Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
Study: NCT02955537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI-BP
Description: MI-BP includes the following components: 1) Home blood pressure monitoring 2) Physical activity monitoring 3) Sodium intake self-monitoring 4) Physical activity and sodium intake goal setting 5) Educational messaging via push notification and in-app messaging 6) motivational messaging 7) tailored messaging relevant to individual participants and 8) medication reminders.
Study: NCT03246685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
Study: NCT02771197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study: NCT01794260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cream from Zingiber cassumunar Roxb. extract

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Study: NCT03411421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-794
Description: AL-794 will be administered as tablets orally on Day 1 to Day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-794
Description: AL-794 will be administered as tablets orally on Day 1 to Day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets will be administered.
Study: NCT03024125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein
Description: To observe the effect of a high protein (HP) diet over muscle mass, fat mass, and strength changes, focusing in differences between the NP and HP groups.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal protein
Description: To observe the effect of a normal protein (NP) diet over muscle mass, fat mass, and strength changes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: The physical strength training will be performed equally by both groups, containing exercises for upper and lower limbs and aiming for hypertrophy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training
Description: The physical strength training will be performed equally by both groups, containing exercises for upper and lower limbs and aiming for hypertrophy.
Study: NCT00386243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioral therapy is delivered by phone by a nurse care-manager 6 times over a 12-week period. Sessions last approximately 45 minutes and occur at weeks 14, 16, 18, 20, 22, and 24 of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain self-management program
Description: The pain self-management program is delivered by a nurse care-manager during a 12-week period. Sessions are each 45 minutes long and phone-based. They occur at baseline, week 1, week 3, week 6, week 9, and week 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-Analgesic Therapy
Description: Amitriptyline, start at 10-25, titrate to 100 mg Nortriptyline, start at 10-25, titrate to 100 mg~Gabapentin, titrate up to 900-1200 tid venlafaxine, carbemazepine, duloxetine, and/or pregabalin~Cyclobenzaprine, titrate to 10 mg TID fluoxetine, sertraline, citalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Analgesics
Description: Tramadol 50 mg BID or TID and titrate to 100 mg QID Acetaminophen/codeine (300mg/30mg). Take 1 or 2 tablets qid prn pain Acetaminophen/hydrocodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Acetaminophen/oxycodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Morphine SR (30mg). Start at 30 mg twice a day (titrate up to 240mg/day if needed) Methadone (5-10mg). Start at 5mg bid; titrate 10mg tid (max 20mg tid)
Study: NCT03143504

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Testing for Atopic eczema
Description: FTIR Spectroscopy. This will involve placing the assessment tool briefly in contact with the baby's skin on the arm and thigh.~Transepidermal Water Loss. This will involve placing a probe on the baby's skin for approximately 60 seconds on the arm and thigh. The probe measures the rate of water loss from the baby's skin, which indicates how well it acts as a barrier.~Collection of skin samples. This will involve collecting surface skin samples using small sticky-tape discs to collect only the very top skin cells that are already dead and about to be shed naturally by the body.~Microbial swab. The researchers will rub the baby's skin gently with a wet sterile swab to collect a sample of the microbes on the baby's skin surface.~Buccal swab / saliva sample. The researchers will collect a sample of the baby's saliva using a buccal swab. This sample will be used to analyse the baby's genes (DNA) to assess their inherited risk of eczema.
Study: NCT03878680

Intervention type: OTHER
Intervention: Study questionnaires
Description: Completion of the International study of Asthma and Allergies in Children(ISAAC)core questionnaires:~1. Core questionnaire on wheezing.~2. Core questionnaire on rhinitis.~3. Core questionnaire on atopic dermatitis.

Intervention type: OTHER
Intervention: Study questionnaires
Description: Completion of the International study of Asthma and Allergies in Children(ISAAC)core questionnaires:~1. Core questionnaire on wheezing.~2. Core questionnaire on rhinitis.~3. Core questionnaire on atopic dermatitis.
Study: NCT02682992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
Study: NCT01629758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denenicokin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denenicokin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denenicokin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT03624595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery in the intensive care unit; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline) infusion is administered in the same rate for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.